Ahmed et al. performed a phase 1 dose-escalation study investigating autologous T cells genetically modified to express HER2-CARs in cytomegalovirus (CMV)-seropositive patients with progressive HER2-positive glioblastoma. This evidence concerns the gene ERBB2 and glioblastoma.